Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
